Kornimate/medical-research-clean huggingface dataset:
imaging of brain structural/functional connectivity and amyloid and tau lesions in apoe4 carriers.

Conditions: Alzheimer Disease

Summary: to advance current knowledge on the vascular contributions to dementia

this is a multi-center study at washington university (wash u), university of southern california (usc), and huntington medical research institute (hmri).the overall goal of both the aa program and the ppg program is to advance current knowledge on the vascular contributions to dementia particularly in individuals with the major genetic risk factor for late-onset ad, i.e., apolipoprotein e-ε4 (apoe4) gene that develop early vascular dysfunction and significant cerebrovascular pathology compared to non-carriers, and establish whether the neurovasculature plays a key role in cognitive decline, and therefore is a key new therapeutic target to treat dementia in apoe4 carriers.

Eligibility criteria:
inclusion criteria: * male or female, any race * age \> 18 years * participation in one of the ongoing projects affiliated with the knight adrc at washington university and referred by the map staff and a washington university physician. * normal cognition or early-stage symptomatic ad * females of childbearing potential without documented history of menopause or hysterectomy who do participate must not be pregnant or breastfeeding at screening * (negative urine β-hcg within 24 hours prior to injection), and must agree to avoid becoming pregnant. females of childbearing potential who do not agree to use reliable contraception or refrain from sexual activity for 24 hours following administration of flortaucipir injection. * enrollment in dce-mri study * capacity to give informed consent and follow study procedures exclusion criteria: * any illness preventing cooperation with testing or longitudinal participation * exclusion from the knight adrc or dian referring project * has a high risk for torsades de pointes or is taking medications known to prolong or may prolong qt interval (refer to study attachment "restricted medication list"). * mri contraindications (e.g. electronic medical devices, severe claustrophobia, inability to lie still for long periods) that make it unsafe to participate in an mri scan, using standard screening processes implemented by washington university and barnes-jewish hospital * currently pregnant or breastfeeding

Keywords: dementia taupathies brain disease mild cognitive impairment neurodegenerative disease
a study of the concurrent use of agn-190584 and agn-199201 in participants with presbyopia

Conditions: Presbyopia

Summary: this study will identify the optimum concentrations of agn-199201 and agn-190584 when dosed in combination once a day for the improvement of uncorrected near visual acuity in participants with presbyopia (inability to focus on items close-up).


Eligibility criteria:
inclusion criteria: -normal vision at distance, either natural or post corneal laser refractive surgery, with presbyopia in each eye and complaints of poor near vision that impacts activities of daily living. exclusion criteria: * use of any topical ophthalmic medications, including artificial tears other than the study medications during the study * corneal abnormalities in either eye that interfere with visual acuity * history of cataract surgery, phakic intraocular lens surgery, corneal inlay surgery or any intraocular surgery * diagnosis of glaucoma or ocular hypertension.
novel surgical checklists for gynecologic laparoscopy in haiti

Conditions: Gynecology; Surgery

Summary: the researchers traveled to university hospital mirebalais in haiti and provided a one week long laparoscopic training and simulation course to the 7 obgyn faculty there. the researchers used novel checklists to help the faculty to set up for laparoscopic cases and care for the equipment needed. the researchers then asked the physicians their opinion of the checklists.


Eligibility criteria:
inclusion criteria: * obgyn physician in haiti exclusion criteria: * none
defining the neural dynamics of concept retrieval using electrocorticography

Conditions: Aphasia

Summary: this study will look at the way activity within the brain changes over time while a person is trying to think about certain everyday concepts. to measure brain activity accurately, we will be using electrodes placed on people's brains during awake brain surgery.

this study will measure the dynamics of cortical activity among early modal cortex and multimodal cortical regions during conceptual retrieval using electrocorticography. participants will be patients undergoing awake temporal lobe craniotomies. during the surgery patients will have multiple high-density grids placed to simultaneously record activity in multiple areas while the patient is performing language tasks. activity in each of these regions will be tested for timing differences and informational directionality to determine the temporal dynamics.

Eligibility criteria:
inclusion criteria: * clinically determined to require an awake left temporal resection of a brain lesion with concurrent language testing. * english as a first language. exclusion criteria: * significant preoperative neuropsychological deficits in memory or naming. * patients with inability to make decisions regarding their participation in this research project. * surgeon does not plan to expose the area of interest or determines that recording during the resection will interfere with his surgical plan.
the metabolism research of klk treating acute cerebral ischemic stroke: focus on drug frequency-efficacy relationship

Conditions: Cerebral Infarction

Summary: evaluate the effectiveness of the of kallikrein in the different drug frequency for acute anterior circulation cerebral infarction.


Eligibility criteria:
inclusion criteria: 1. age 18 to 80 years old; 2. first time diagnosed or have history of acute anterior circulation cerebral infarction without serious sequelae (mrs = 0-2); 3. acute anterior circulation cerebral infarction with large artery atherosclerotic etiology; 4. ability to randomize within 48 h of time last known free of new ischemic symptoms. 5. national institute of health stroke scale(nihss) ranges from 7 to 22; 6. signed written informed consent. exclusion criteria: 1. cerebral ct shows cerebral hemorrhage disease: cerebral hemorrhage, subarachnoid hemorrhage, etc.; 2. transient ischemic attack; 3. serious disturbance of consciousness: glasgow coma scalegcs（gcs）≤8; 4. combined angiotensin-converting enzyme inhibitor(acei) less than 5 half-time (according to its instruction), or need to be treated with acei; 5. past or present suffering from hemorrhagic tendency of the disease; 6. the investigator in consideration of the other condition that the patients doesn't fit to participate in this clinical study.

Keywords: cerebral infarction kallikrein klk
desflurane and brain relaxation in craniotomy

Conditions: Supratentorial Tumor

Summary: optional brain relaxation improves the surgeon's operating conditions and is likely to minimize the degree of retraction injury ,with the potential for providing patients with a better outcome. the choice of anesthetic drugs can affect intraoperative brain relaxation. propofol suppresses brain metabolism, reduces cerebral blood flow, and provides satisfactory brain relaxation. desflurane is often criticized in neurosurgery due to its cerebral vasodilation and potential to increase intracranial pressure, however, it has been found to have a little clinical significance. this study intends to compare the effects of desflurane with propofol on brain relaxation in patients with supratentorial tumors under mild hyperventilation, and to provide new clinical evidence for the use of desflurane in neurosurgical anesthesia.

to compare the effect of desflurane versus propofol combined with remifentanil anesthesia on brain relaxation in patients undergoing supratentorial tumor surgery with mild hyperventilation, and compare the emergence time and common complications during recovery.

Eligibility criteria:
inclusion criteria: * 18-60 years * scheduled for elective craniotomy for supratentorial cerebral tumors * asa status i-iii * glasgow score of 15 * no clinical signs of intracranial hypertension * preoperative brain imaging (ct or mri) with midline shift less than 5mm * informed consent signed by patients exclusion criteria: * scheduled intraoperative motor evoked potential monitoring * patients with cerebral vascular diseases * uncontrolled cardiopulmonary disease * schedule to retain tracheal intubation after surgery * unable to comprehend and cooperate with the examination * bmi \> 30 kg/m-2 * emergency surgery * history of related anesthetic allergy
fascia iliaca compartment block in acute and chronic pain management in hip fracture patients

Conditions: Chronic Hip Pain

Summary: this study evaluates the effect of fascia iliaca compartment block (ficb) in the management of acute post -surgical pain in hip fracture patients and in the appearance of chronic post -surgical hip pain, by means of von korff graded chronic pain scale -modified for hip pain in greek. half of the patients will not receive fascia iliaca compartment block.


Eligibility criteria:
inclusion criteria: * asa i-iii (american society of anesthesiologists classification) * intertrochanteric fractures * fractures of femoral neck exclusion criteria: * existing pain in hip joint to be operated * cognitive or mental disorder * administration of analgesic drugs prior surgery * contraindications of spinal anesthesia * refusal to participate in the study
a study to compare db-1303/bnt323 versus t-dm1 in breast cancer

Conditions: HER2-positive Breast Cancer

Summary: this study is designed to compare efficacy and safety of db-1303/bnt323 versus t-dm1 in her2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.

this is a randomized controlled, 2-arm, open-label, multicenter phase iii study to assess the efficacy and safety of db-1303/bnt323 versus trastuzumab emtansine (t-dm1) in patients with human epidermal growth factor receptor 2 (her2) -positive unresectable/metastatic breast cancer who have been treated with trastuzumab and taxanes. approximately 224 patients with unresectable or metastatic her2-positive breast cancer will be randomized 1:1 to receive db-1303/bnt323 or t-dm1, respectively.

Eligibility criteria:
inclusion criteria: * male or female adults ≥ 18 years at the time of voluntary signing of informed consent. * pathologically confirmed unresectable or metastatic her2 positive breast cancer previously treated with trastuzumab and taxane * eastern cooperative oncology group (ecog) performance status score is 0 or 1. * presence of at least one measurable lesion according to recist v1.1 * expected survival time ≥ 12 weeks. * patients must give informed consent to this study and voluntarily sign written informed consent form prior to the study. exclusion criteria: * prior anti-her2 adc therapy. * previous history of interstitial lung disease/noninfectious pneumonitis/radiation pneumonitis requiring steroid therapy. * known serious hypersensitivity to the active ingredients of the study drug, inactive ingredients in the formulation, or other antibody drugs. * multiple primary malignancies within 3 years, except for adequately resected non-melanoma skin cancer, curatively treated in situ tumor, or contralateral breast cancer * uncontrolled infection requiring intravenous antibiotics, antiviral or antifungal agents, autoimmune disease requiring treatment, uncontrolled diabetes, hypertension, or other systemic disease that makes compliance with study procedures difficult * unrecovered toxicity from prior anticancer therapy, defined as toxicity (except for alopecia) not recovered to ≤grade 1 (nci-ctcae v5.0) or baseline. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: her2-positive breast cancer bc
toripalimab with preoperative chemoradiotherapy for la-egj

Conditions: PD-1; Chemoradiotherapy; Gastroesophageal Junction Cancer

Summary: this study aims to investigate the safety and efficacy of radiotherapy combined with toripalimab (pd-1 inhibitor) in the treatment of locally advanced adenocarcinoma of the gastroesophageal junction.

in this study, patients with locally advanced adenocarcinoma of gastroesophageal junction will be enrolled to explore the safety and efficacy of preoperative radiotherapy and chemotherapy combined with toripalimab (pd-1). around 45 patients will be recruited in this one-arm cohort. all patients in this cohort will be treated with preoperative radiotherapy and chemotherapy plus pd-1 for two times, then another two times of pd-1 before operation. after surgery, postoperative chemotherapy plus pd-1 will be carried out for four times. this study focuses on the safety of chemoradiotherapy combined with immunotherapy, and whether the trg grade, lc, dfs have been improved.

Eligibility criteria:
inclusion criteria: * 1) age 18-75, male and female. 2) ecog score was 0-1. 3) diagnosis of adenocarcinoma in the gastroesophageal junction. 4) initial treatment of locally advanced patients (ct3-4 or n+, and m0). 5) the estimated survival time will be more than 12 months. 6) adequate organ reserve function. 7) agree to join the group, willing to cooperate with clinical research, and sign the informed consent. exclusion criteria: * 1) patients have received immunotherapy, such as pd-1 antibody, pd-l1 antibody and ctla4 antibody. 2) immunosuppressive drugs were used within 4 weeks before admission. 3) active infection, acute myocardial infarction in recent 6 months, severe arrhythmia requiring long-term drug intervention, severe stroke, uncontrolled epilepsy or other serious medical complications. 4) in the past five years, there have been other malignant diseases except for cured skin cancer and cervical cancer in situ.
efficacy study of magnetic resonance (mr) guided focused ultrasound in the treatment of large fibroids

Conditions: Uterine Fibroids

Summary: the purpose of this study is to determine whether ablation of uterine fibroids with mr guided focused ultrasound following 3 months pre-treatment with gonadotrophin releasing analogues will allow the effective use of this therapy in women with larger fibroids.


Eligibility criteria:
inclusion criteria: * subject has given consent * willing and able to attend all visits * minimum age 18 with no desire for future fertility * uterine fibroid \> 300 cc on mri * normal cervical smear * screening symptom score \>21 * pre or peri-menopausal * fibroids being device accessible exclusion criteria: * pregnancy * previous gnrh treatment * hrt use * hormonal contraception * patient on dialysis * haematocrit \<25 * asa score \> 2 * severe cerebrovascular disease * anticoagulated * active pelvic infection or history of pid * weight\> 250 lbs * any contra-indication to mr imaging * intolerance to mri contrast agent * unable to remain in prone positions for 3hours * iucd * abdominal scarring in beam pathway * breast feeding * non-perfused fibroid on contrast enhanced images

Keywords: magnetic resonance guided focused ultrasound gonadotrophin releasing hormone agonist uterine fibroids
wilstim - dbs (wilson stimulation - deep brain stimulation)

Conditions: Severe Dystonia; Wilson's Disease

Summary: dystonia in wilson's disease represent a major issue. the persistence of disabling motor symptoms despite medical treatments justifies conducting a study on deep brain stimulation (dbs) in wilson's disease (wd). for bradykinetic patients, subthalamic nucleus (stn) could be considered as a better target than the globus pallidus (gpi). for patients with hyperkinetic dystonia, the internal globus pallidus (gpi) will be chosen as the target of dbs. the investigators hypothesize that stn dbs will improve wilson's disease patients, who, despite copper chelators drugs, are still impaired by severe dystonia and akinesia (more or less associated with other movement disorders). the investigators primary objective is to demonstrate the efficacy of stn/gpi dbs on dystonia associated with wilson's disease. secondary objectives: * to evaluate the impact of stn/gpi dbs on other movements disorders (tremor, parkinsonism, chorea) observed in wilson's disease. * to describe cognitive status of patients and to evaluate the consequences of stn/gpi dbs on cognition and behavioral aspects of the disease. * to evaluate the consequences of the stimulation on speech and swallowing. * to evaluate the social impact of stn/gpi dbs in wilson's disease. * to evaluate the safety of stn/gpi dbs in the specific context of wilson's disease.

4 periods of stimulation on and off, sequence randomized at day 0.

Eligibility criteria:
inclusion criteria: * age \> 18 and \< 60 years. * severe neurological form of wilson's disease with predominant dystonia and akinetic-rigid syndrome, despite optimized treatment stabilized for at least 6 months. * important disability due to abnormal movements (rankin score=2 to 4). * absence of dementia (mms \> 24 and bref \> 15). * stable psychiatric status and absence of severe depression (bdi \<28). * social security coverage. * signature of informed consent. (signature of legal guardian for subjects under protection) exclusion criteria: * severe hepatopathy with coagulation disorders (platelet count \ 1.5; v factor deficit; low level of fibrinogen \< 1g/dl; increased of fibrin degradation products; low level of antithrombin). * liver transplanted patients \< 2 years * patients under immunosupressive drugs and corticoids regimen. * participation to another biomedical research involving any drugs. * severe and uncontrolled psychosis or depression. * major atrophy on brain mri that could represent a problem for leads implantation. * necrosis of the stn/gpi on brain mri. * female subjects who are pregnant or lactating.

Keywords: wilson's disease deep brain stimulation dystonia
comparison of ferrous sulfate, polymaltose complex and iron-zinc in iron deficiency anemia

Conditions: Iron Deficiency Anemia

Summary: the aim of the present study was to compare the effectiveness of the different oral iron preparations in children with ida.

iron deficiency (id) is the most common cause of the anemia throughout the world, with almost half of the population in developing countries suffering from id. children with iron deficiency anemia (ida) may have functional consequences including impaired motor and physical growth. in the case of ida, the underlying cause should be identified and treated. iron supplementation remains an important strategy for the prevention and treatment of ida and can produce substantial improvements in the functional performance of iron deficient individuals. the iron-containing preparations available on the market vary widely in dosage, salt, and chemical state of iron (ferrous or ferric form). current treatment strategy for ida involves the oral use of fe2+ salts (fe so4) and fe3+ polymaltose complexes (feoh3). most of these preparations vary in their bioavailability, efficacy, side effects, and cost. animal studies have not shown any significant difference in their oral bioavailability. however, in clinical practice, bivalent iron salts such as ferrous sulfate (fe-s), ferrous gluconate, and ferrous fumarate are more widely used and are preferred over ferric iron preparations. fe-s preparations usually present good bioavailability (between 10 and 15 %), while bioavailability of ferric iron preparations is 3 to 4 times less than that of conventional fe-s. this is due to the extremely poor solubility of ferric iron in alkaline media and the fact that ferric iron needs to be transformed into ferrous iron before being absorbed. for this reason, among ferrous preparations, fe-s remains the established and the standard treatment of id due to its acceptable tolerability, high effectiveness, and low cost. the aim of the present study was to compare the effectiveness of the different oral iron preparations in children with ida.

Eligibility criteria:
inclusion criteria: * the children with ida, aged between 6 months and 15 years, were randomly included in fe-s (ferro sanol® sp.)(group i), fe-oh-pm (santafer® sp.)(group ii), and fe-zn (ferro zinc® sp.)(group iii). ida was defined as hemoglobin (hgb), serum iron and ferritin levels below -2sd according to age and gender. exclusion criteria: * the main exclusion criteria were anemia due to other causes except ida * severe concurrent illness (cardiovascular, renal, and hepatic) * known hypersensitivity to ferrous or ferric preparations * malignancy of any type * children with thalassemia major, sickle cell anemia or other hemoglobinopathies, hemolytic anemia or aplastic or hypoplastic anemia.

Keywords: anemia iron polymaltose complexes iron zinc
mcg is clinically applied to evaluate myocardial ischemic function in patients with stable coronary artery disease

Conditions: Stable Coronary Artery Disease

Summary: the objective of this observational study is to evaluate the diagnostic effectiveness of magnetocardiography (mcg) in patients with stable coronary artery disease (scad) and compare it with coronary cta (ccta). additionally, the study aims to determine the most suitable diagnostic index for mcg. the primary question it seeks to address is whether mcg or mcg combined with ccta can be utilized to guide the clinical application of percutaneous coronary intervention (pci) for coronary heart disease.

1. patients aged≥18 years with stable coronary artery disease (ccta stenosis 30%-90%) underwent sequential examinations of mcg and ccta. the results of ccta were assessed using ct-ffr, and the diagnostic effectiveness of mcg in evaluating myocardial ischemia was analyzed using ct-ffr as the reference standard. simultaneously, mcg was compared to ccta to determine the clinical value of mcg in the functional evaluation of myocardial ischemia. 2. coronary angiography was performed in patients who met the criteria for the procedure, and revascularization was carried out based on the intraoperative situation. patients who underwent revascularization were followed up for 1 year, with major adverse cardiovascular events (mace) as the endpoint. the clinical value of mcg in guiding the treatment of patients with scad was evaluated by reviewing the proportion of coronary angiography, revascularization, and mace in the enrolled patients.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years old. 2. stable coronary artery disease patients with a coronary cta stenosis degree of 30% to 90%. 3. sign informed consent. exclusion criteria: 1. patients diagnosed with acute coronary syndrome. 2. patients diagnosed with hypertrophic cardiomyopathy. 3. patients diagnosed with dilated cardiomyopathy. 4. patients with complex arrhythmias, such as frequent atrial premature beats, ventricular premature beats, and complete bundle branch block. 5. patients with a left ventricular ejection fraction less than 50%. 6. patients with chronic obstructive pulmonary disease, heart failure, kidney failure, or other serious diseases. 7. pregnant women. 8. patients with an allergy to contrast agents. 9. the study subjects who have metal grafts that interfere with magnetic cardiogram examination. 10. the study subjects who are unable to cooperate with magnetocardiogram examination and cta. 11. patients who have undergone coronary artery bypass grafting. 12. there are significant artifacts present in coronary cta.

Keywords: stable coronary artery disease magnetocardiography coronary cta